Chemicals in green tea may help inhibit development of prostate cancer in men at high risk, according to results of a randomized, controlled trial.
The trial, which was funded by the National Institutes of Health/National Cancer Institute, was presented at the American Society of Clinical Oncology annual meeting in Chicago and also published online in Cancer Prevention Research (April 14, 2015).
Researchers from Moffitt Cancer Center, Tampa, FL, evaluated the effects of a year of treatment with catechins, substances in green tea that have interfered with the growth and functioning of cancer cells and promoted cell death in laboratory studies and prevented and decreased tumor growth in animals.
They studied 97 men with high-grade prostatic intraepithelial neoplasia (HGPIN) and/or atypical small acinar proliferation (ASAP), who were randomized to receive Polyphenon E (49 men), 200 mg twice a day, or placebo (48 men) for a year. Polyphenon E is a proprietary, standardized green tea extract containing a mixture of catechins, primarily the most potent catechin, epigallocatecin-3-gallate (EGCG).
More on Prostate Cancer